Search results: (10000)
News Efficacy and Safety of Levodopa/Entacapone/Carbidopa Combination in the Treatment of Advanced Parkinson's Disease – Prospective ELEGANCE Study
Therapy for advanced Parkinson's disease (PD) with a triple combination of levodopa/entacapone/carbidopa in the form of intestinal gel (LECIG) was first introduced to the Swedish market in 2018. The German team behind the ELEGANCE study aimed to gather available data and analyze the efficacy and safety of this modality in the long-term treatment of PD.
News First Experiences with the Combination of Levodopa/Entacapone/Carbidopa in Intestinal Gel from the Perspective of Patients with Parkinson's Disease
The work presented at the 8th Congress of the European Academy of Neurology (EAN) in Vienna in June 2022 summarizes the first experiences with the use of intestinal gel combining the active ingredients levodopa/entacapone/carbidopa in patients with Parkinson’s disease (PD) in clinical practice in Austria.
News ESC 2022: Evidence of SGLT2i Effectiveness in HFrEF Treatment is Growing: How to Integrate Them into Routine Practice?
Although the need for pharmacotherapeutic options for patients with heart failure with reduced left ventricular ejection fraction (HFrEF) is essential, challenges in implementing this medication according to guidelines persist. This issue was also discussed at a symposium held as part of this year's European Society of Cardiology Congress (ESC 2022).
News ESC 2022: SGLT2 Inhibitors as Hope for HFpEF: How to Implement Them in Practice?
Patients with heart failure (HF) can significantly benefit from the inclusion of sodium-glucose co-transporter 2 inhibitors (SGLT2i, i.e., gliflozins) in their treatment strategy according to current findings. This also applies to patients with preserved left ventricular ejection fraction (HFpEF). At the ESC 2022 congress, useful information for practical applications was presented in addition to study data. For illustration, we bring a case study from a German practice.
News Protective Effect of SGLT2 Inhibitors on Heart Muscle Function - Findings from a Recent Meta-analysis
Sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) primarily offer the ability to achieve very good glycemic control with a low risk of hypoglycemia. Their undeniable advantage, however, is their cardiovascular safety and renoprotective effect. The impact of gliflozins on heart functions has already been the subject of many studies, the findings of which are summarized in a recently published meta-analysis.
News Alpha-1 Antitrypsin Deficiency and Lung Disease in Patients with Primary Immunodeficiencies
Alpha-1 antitrypsin deficiency (AATD) plays a significant role in the pathogenesis of pulmonary emphysema, chronic obstructive pulmonary disease (COPD), and bronchiectasis. However, its deficiency may also play a role in other lung diseases.
News Can identifying alpha-1 antitrypsin deficiency before liver transplantation extend survival?
Alpha-1 antitrypsin deficiency (AATD) can manifest (among other things) as liver cirrhosis. The study presented below examined the survival of patients diagnosed with AATD before and after liver transplantation.
News Expression of PD-L1 as a Predictive Biomarker for Therapy Selection in mRCC
A newly published systematic review and meta-analysis of studies involving patients with metastatic renal cell carcinoma (mRCC) evaluates the predictive significance of PD-L1 expression in the treatment with immune checkpoint inhibitors.
News Negative Symptoms of Schizophrenia and Their Assessment
Schizophrenia is a serious psychiatric disorder with a prevalence of up to 1%. It can manifest with both negative and positive symptoms. We briefly summarize the clinical assessment and rating scales of negative symptoms in the following text.
News Von Willebrand Disease as a Cause of Abnormal Uterine Bleeding
Abnormal uterine bleeding constitutes a large portion of complaints among women of reproductive age. This type of bleeding is typical for von Willebrand disease (vWD), but also for other types of coagulation disorders. So, is vWD more frequent in women with abnormal uterine bleeding than in the general population?
News Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease
Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is estimated that a 60-year-old patient with T2DM loses an average of 6–7 years of life compared to a person of the same age without T2DM. What impact does modern pharmacotherapy have on this adverse balance?
News Dabigatran Etexilate in the Treatment of Acute Thromboembolic Disease in Children
Until now, standard anticoagulants such as low-molecular-weight heparin or unfractionated heparin and others have been used in pediatric patients for the treatment of thromboembolism. The study presented below aimed to determine whether dabigatran could be the drug of the future in the treatment of pediatric patients with thromboembolism.
News When to Stop Dabigatran Anticoagulation Treatment Before Catheter Ablation in Patients with Atrial Fibrillation?
Catheter ablation is now a standard method of treating atrial fibrillation. Its most common complications are bleeding and thromboembolism. The aim of the analysis of 2 clinical studies presented below, whose conclusions were recently published, was to determine the optimal timing of stopping dabigatran anticoagulation treatment before this procedure.
News Dust Mite Allergies: Common Does Not Mean Trivial
Dust mite allergies are almost ubiquitous problems that we perceive as part of the 'broader norm.' However, patients do not see it this way, so we should not lose sight of it.
News Teriflunomide vs. Dimethyl Fumarate in Real Practice: We Know the Winner! Will It Surprise You?
Teriflunomide and dimethyl fumarate are disease-modifying drugs (DMDs) used in the treatment of multiple sclerosis (MS). Regarding the course, form, and severity of MS, their target groups are comparable in their characteristics. These DMDs are therefore ideal candidates for mutual comparison. Swedish authors decided to compare their effectiveness based on data from real clinical practice obtained through the Swedish National Registry.